Organ Recovery Systems’ LifePort® Kidney Transporter Awarded Exclusive Contract for Kidney Transplant Preservation Services in Belgium
Surgeons at Universitaire Ziekenhuizen and AZ Universitair Ziekenhuis have successfully performed the first kidney transplant procedures as part of a national contract with Organ Recovery Systems that designates the Company as the exclusive provider of preservation services for donor kidneys designated for clinical transplantation. The arrangement calls for the use of the Company’s proprietary LifePort Kidney Transporter at all transplant centers throughout Belgium along with logistical support services. LifePort Kidney Transporter is a novel medical device for organ preservation and transportation that employs hypothermic machine perfusion (HMP) to improve viability of a donor organ during the crucial window of time between organ donation and transplantation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221012005337/en/
The LifePort Kidney Transporter will be the exclusive provider of kidney preservation services at 7 transplant centers across Belgium. (Photo: Business Wire)
Organ Recovery Systems was awarded the National “All-inclusive kidney preservation platform for hypothermic perfusion of donor kidneys for transplantation” by the National Belgian Transplant Society.
Starting October 1st, 2022, through 2025, Organ Recovery Systems will provide all-inclusive preservation services for all Belgium-based transplant centers, including:
- Universitaire Ziekenhuizen Leuven
- AZ Universitair Ziekenhuis Antwerpen, Edegem
- Universitair Ziekenhuis Brussel, Campus Jette
- Université Libre de Bruxelles, Hôpital Erasme
- Universitair Ziekenhuis Gent, Gent
- Cliniques Universitaires Saint Luc, Bruxelles
- Centre Hospitalier Universitaire, Liège
“By establishing LifePort Kidney Transporter as the standard perfusion technology in Belgium, we’re going to show the world what the future of organ preservation looks like,” says Professor Tom Darius of Cliniques Universitaires Saint-Luc. “LifePort Kidney Transporter gives us the best shot at extending and improving the lives of people in need of a kidney transplant.”
This announcement underlines Belgium’s position as a clinical leader in progressive transplant solutions after being one of the first European Nations to enact a program allowing the use of organs from individuals previously deemed ineligible for donation: those who died from circulatory death (DCD). Although organs from these donors were historically considered unviable, a retrospective analysis revealed that HMP, as enabled by LifePort Kidney Transporter, improved DCD kidney graft function compared to traditional static cold storage, making these organs more suitable for transplantation. Adopting LifePort Kidney Transporter as a standard of care for kidney preservation highlights Belgium’s commitment to increasing access to life-saving organs, improving patient outcomes, and honoring each donor and donor family for their precious gift.
“We are deeply honored to see our LifePort technology contributing to the process of life-saving transplantation at a national level in Belgium,” said David Kravitz, CEO of Organ Recovery Systems. “As our Company’s mission is to help improve outcomes in transplantation, we are grateful to have the opportunity to partner with the National Belgian Transplant Society in giving more transplant waiting list patients a second chance at life.”
About Organ Recovery Systems
Organ Recovery Systems is a global market-leading provider of organ preservation products and services, supporting 320 transplant programs across 43 countries. Since its launch in 2003, LifePort Kidney Transporter has been employed in over 175,000 renal transplant procedures worldwide. Organ Recovery Systems’ proprietary LifePort platform has also been successfully designed to accommodate donor livers to help improve transplant outcomes for end-stage liver disease patients. LifePort Kidney and Liver Transporters are among a growing family of products and services developed by Organ Recovery Systems to support the Company’s mission of honoring donation as a gift of life, improving outcomes, and helping lower overall costs of care for end-stage organ disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005337/en/
Contact information
CG Life
Sarah Mishek
SMishek@CGLife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom